


Ulimorelin

Cat. No.:	HY-14903
CAS No.:	842131-33-3
Molecular Formula:	C ₃₀ H ₃₉ FN ₄ O ₄
Molecular Weight:	538.65
Target:	GHSR; Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC ₅₀ of 29 nM and a K _i of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α ₁ -adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition ^{[1][2][3]} .								
In Vivo	<p>Ulimorelin (TZP-101; 0.3-5 mg/kg; i.v.) causes a dose dependent increase in the numbers and amplitudes of phasic pressure waves recorded from the colorectum^[1].</p> <p>Ulimorelin (1, 3, 5 mg/kg; i.v.) causes a substantial and prolonged (~1 h) increase in colorectal propulsive activity and expulsion of colonic contents^[1].</p> <p>Ulimorelin (p.o.; 8 mg/kg) has a C_{max} of 0.39 μM and a AUC of 82 μM•min for rats. Ulimorelin (i.v.; 2 mg/kg) has a T_{1/2} of 50 mins, a CL of 24 mL/min/kg, and a V_{ss} of 1.7 L/kg for rats^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague-Dawley rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.3, 1, 3, 5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.</td> </tr> <tr> <td>Result:</td> <td>Caused a dose dependent increase in the numbers and amplitudes of phasic pressure waves recorded from the colorectum.</td> </tr> </table>	Animal Model:	Male Sprague-Dawley rats ^[1]	Dosage:	0.3, 1, 3, 5 mg/kg	Administration:	i.v.	Result:	Caused a dose dependent increase in the numbers and amplitudes of phasic pressure waves recorded from the colorectum.
Animal Model:	Male Sprague-Dawley rats ^[1]								
Dosage:	0.3, 1, 3, 5 mg/kg								
Administration:	i.v.								
Result:	Caused a dose dependent increase in the numbers and amplitudes of phasic pressure waves recorded from the colorectum.								

REFERENCES

- [1]. Pustovit RV, et al. The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. *Neurogastroenterol Motil.* 2014 Feb;26(2):264-71.
- [2]. Broad J, et al. Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. *Eur J Pharmacol.* 2015 Apr 5;752:34-9.
- [3]. Hoveyda HR, et al. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. *J Med Chem.* 2011 Dec 22;54(24):8305-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA